FNY Investment Advisers LLC Buys Shares of 3,000 argenx SE – (ARGX)

FNY Investment Advisers LLC bought a new stake in shares of argenx SE – (NASDAQ:ARGX) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 3,000 shares of the company’s stock, valued at approximately $374,000.

Other hedge funds have also added to or reduced their stakes in the company. We Are One Seven LLC bought a new position in shares of argenx during the 4th quarter valued at $27,000. Partner Investment Management L.P. bought a new stake in argenx in the 4th quarter worth $110,000. Virtu Financial LLC bought a new stake in argenx in the 1st quarter worth $217,000. JGP Global Gestao de Recursos Ltda. bought a new stake in argenx in the 4th quarter worth $202,000. Finally, Brown Advisory Securities LLC bought a new stake in argenx in the 4th quarter worth $217,000. 63.72% of the stock is currently owned by institutional investors.

NASDAQ:ARGX opened at $115.00 on Thursday. argenx SE – has a 12 month low of $63.81 and a 12 month high of $135.58. The stock has a market capitalization of $3.87 billion, a PE ratio of -48.94 and a beta of 1.23.

ARGX has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of argenx from a “hold” rating to a “buy” rating and set a $102.00 price target on the stock in a report on Tuesday, December 25th. Stifel Nicolaus reissued a “buy” rating on shares of argenx in a report on Monday, February 4th. Morgan Stanley initiated coverage on shares of argenx in a report on Friday, January 4th. They issued an “overweight” rating and a $140.00 price target on the stock. SunTrust Banks reissued a “buy” rating on shares of argenx in a report on Friday, January 18th. Finally, Wedbush raised their price target on shares of argenx from $131.00 to $144.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. One investment analyst has rated the stock with a sell rating and thirteen have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $140.91.

TRADEMARK VIOLATION NOTICE: “FNY Investment Advisers LLC Buys Shares of 3,000 argenx SE – (ARGX)” was originally published by WKRB News and is the property of of WKRB News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.wkrb13.com/2019/04/18/fny-investment-advisers-llc-buys-shares-of-3000-argenx-se-argx.html.

argenx Profile

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Article: Back-End Load

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenx SE – (NASDAQ:ARGX).

Institutional Ownership by Quarter for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.